Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings, Inc. (XERS) — VMCI valuation read

XERS screens at VMCI 46/100, a 4-point gap below the Healthcare sector median (50). For a mid-cap Xeris Biopharma Holdings, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

XERS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: XERS trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.7x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Xeris Biopharma Holdings, Inc..

XERS rose 2.5% over the trailing 7 days, with a -4.7% read on a 30-day basis.